HF exhibits a multi-target profile, acting on p53/MDM2 [63], ROS/JNK [64,84], NF-κB [64,84], and CK2 [72], which could offer reduced potential for single-target resistance, lower therapeutic doses via pathway convergence, and possibly an improved toxicity profile, as suggested by the absence of overt adverse effects in available xenograft studies [64,83,84]. Here, TP53 is linked to hydrops fetalis.